Juno Therapeutics Inc. (JUNO) was reiterated an ‘Outperform’ by FBR Capital analysts on Friday. The broker however, cut its price target on the stock to $61 from $73 after the biopharmaceutical company received notice from the U.S Food and Drug Administration to halt a phase 2 study on a potential cancer treatment following two patients deaths.
The treatment, JCAR015, was Juno’s most advanced drug candidate, and now its outlook is unclear, a factor that is heavily affecting the company’s stock. Shares of Juno Therapeutics plunged more than 31 percent Friday morning.
JUNO was also downgraded to ‘Neutral’ from ‘Overweight’ at JPMorgan (JPM). The firm cut almost in half its price target for the shares to $39 from $63 following the news.
—
Tesla Motors, Inc. (TSLA) was reiterated as ‘Sector Perform’ with a $210 from $220 price target on Friday by RBC Capital Markets. Based on their recent tour, firm believes Tesla’s Model X still has production issues.
Tesla gained $1.37 to $217.31 in mid-day trading today. Approximately 3.5 million shares have already changed hands, compared to the stock’s average daily volume of 5 million shares.
In the past 52 weeks, shares of Palo Alto, California-based electric car maker have traded between a low of $141.05 and a high of $286.65 with its 50-day MA and 200-day MA located at $216.12 and $213.94 levels, respectively.
TSLA currently prints a one year loss of about 15 percent, and a year-to-date loss of around 10 percent.
—
In a report published Friday, Wedbush analysts initiated coverage on Yelp Inc. (YELP) with a ‘Neutral’ rating and $30 price target. Firm believes the company’s platform, which connects people with local businesses, will experience continued user growth due to network effects, Millennial shopping habits, and popular mobile product.
Currently there are 13 analysts that rate YELP a ‘Buy’, 20 rate it a ‘Hold’. Two analysts rate it a ‘Sell’. YELP has a median Street price target of $26.00 with a high target of $46.00.
In the past 52 weeks, shares of San Francisco California-based firm have traded between a low of $14.53 and a high of $36.08 and are now at $30.24.
Shares are down 15.14% year-over-year ; up 4.31% year-to-date.
—
Analysts at Wells Fargo (WFC) downgraded Citigroup Inc. (C) from ‘Outperform’ to ‘Market Perform’ in a research report issued to clients this morning.
On valuation measures, Citigroup Inc. stock it’s trading at a forward P/E multiple of 7.84x, and at a multiple of 8.38x this year’s estimated earnings. The t-12-month revenue at Citigroup Inc. is $66.93 billion. Citi ‘s ROE for the same period is 7.23%.
Shares of the $123.12 billion market cap bank are down 21.48% year-over-year and 20.03% year-to-date.
Citigroup Inc., currently with a median Street price target of $54.50 and a high target of $68, rose $0.67 to $41.955 in recent trading.
—
Analysts at Bernstein are out with a report today upgrading shares of Intel Corporation (INTC) with a ‘Market Perform’ from ‘Underperform’ rating. The firm also raised its price target to $30 from $26 on shares of the Santa Clara, CA-based chipmaker. Intel was also raised to $34 from $33 at RBC Capital Markets.
Intel Corp. recently traded at $33.95, a gain of $0.75 over Thursday’s closing price. The name has a current market capitalization of $160.31 billion.
As for passive income investors, the company pays shareholders $1.04 per share annually in dividends, yielding 3.18%. Five year average dividend yield currently stands at 3.28%.
Leave a Reply